Product Code: 5247
The CRO mass spectroscopy services market is expected to grow significantly by 2028 on account of technological advancements in spectrometers to deliver high-resolution results. In addition, rising concerns regarding food safety among consumers and increasing number of chronic diseases are likely to further boost industry expansion over the forecast period.
Following the coronavirus outbreak, the CRO mass spectroscopy services market has seen notable growth due to high demand for mass spectroscopy for testing applications in the pharmaceutical and biopharmaceutical sectors. Additionally, prominent collaborations for outsourcing contract research organization (CRO) mass spectroscopy to support research and development activities for rapid testing have played a vital role in business growth.
Moreover, key participants in the industry have been focusing on reducing their testing time and improving result accuracy to gain a better footing in the sector, thereby enhancing overall business dynamics. For instance, in June 2020, Alturas Analytics, Inc., a bioanalytical laboratory service provider, introduced low-flow LC-MS/MS to improve the operational functionality of bioanalytic laboratories. For this purpose, the company decided to include an OptiFlow ion source, intended for microflow of SCIEX Triple Quad 7500 LC-MS/MS systems, the QTRAP Ready, due to its greater sensitivity and dynamic variety.
In another instance, in April 2022, Charles River Laboratories (CRL), a leading pharma company, signed a USD 295 million deal with Explora Biolabs, a premier provider of contract vivarium research facilities, to boost its business in San Francisco and Boston. With this move, CRL intended to expand its Charles River Accelerator and Development Lab (CRADL) business.
The CRO mass spectroscopy services market has been bifurcated in terms of service type, end-use, and region. By service type, the market has been further categorized into proteomics services, metabolomics services, and others. The metabolomics services sub-segment is expected to generate about USD 316.2 million in revenue by 2028.
Based on end-use, the CRO mass spectroscopy services market has been segregated into medical device companies, pharmaceutical & biopharmaceutical companies, and others. In 2021, the medical device companies sub-segment held around 17.5% market share and is likely to observe strong growth between 2022 and 2028 due to the prevalent trend of collaborations among companies to facilitate technological advancements.
With respect to region, the Latin America CRO mass spectroscopy services industry accounted for approximately 4% of the global market in terms of revenue in 2021 and is slated to attain a sizable valuation by the end of 2028. Meanwhile, the Middle East & Africa CRO mass spectroscopy services market is anticipated to grow at a CAGR of over 13.9% through the study timeframe.
Table of Contents
Chapter 1 Methodology
- 1.1 Methodology
- 1.2 Base estimates & working
- 1.2.1 North America
- 1.2.2 Europe
- 1.2.3 Asia Pacific
- 1.2.4 Latin America
- 1.2.5 Middle East & Africa
- 1.3 Forecast parameters
- 1.4 Data sources
- 1.4.1 Secondary
- 1.4.1.1 Paid sources
- 1.4.1.2 Unpaid sources
- 1.4.2 Primary
Chapter 2 Executive Summary
- 2.1 CRO mass spectroscopy services industry 360 degree synopsis, 2017 - 2028
- 2.1.1 Business trends
- 2.1.2 Service type trends
- 2.1.3 End-use trends
- 2.1.4 Regional trends
Chapter 3 CRO Mass Spectroscopy Services Market Industry Insights
- 3.1 Industry segmentation
- 3.2 Industry landscape, 2017 - 2028 (USD Million)
- 3.3 Industry impact forces
- 3.3.1 Growth drivers
- 3.3.1.1 Technological advancements
- 3.3.1.2 Growing outsourcing of R&D activities
- 3.3.1.3 Growing clinical trials worldwide
- 3.3.2 Industry pitfalls & challenges
- 3.3.2.1 Intellectual property right issues
- 3.3.2.2 Shortage of skilled professionals
- 3.4 Growth potential analysis
- 3.4.1 By service type
- 3.4.2 By end-use
- 3.5 Porter's analysis
- 3.6 Competitive landscape, 2021
- 3.6.1 Competitive matrix analysis, 2021
- 3.7 PESTEL analysis
Chapter 4 CRO Mass Spectroscopy Services Market, By Service Type
- 4.1 Key segment trends
- 4.2 Proteomics services
- 4.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.3 Metabolomics services
- 4.3.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.3.2 Others
- 4.3.2.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 5 CRO Mass Spectroscopy Services Market, By End-use
- 5.1 Key segment trends
- 5.2 Pharmaceutical & biopharmaceutical companies
- 5.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 5.3 Medical device companies
- 5.3.1 Market size, by region, 2017 - 2028 (USD Million)
- 5.4 Others
- 5.4.1 Market size, by region, 2017 - 2028 (USD Million)
Chapter 6 CRO Mass Spectroscopy Services Market, By Region
- 6.1 Key regional trends
- 6.2 North America
- 6.2.1 Market size, by country, 2017 - 2028 (USD Million)
- 6.2.2 Market size, by service type, 2017 - 2028 (USD Million)
- 6.2.3 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.2.4 U.S.
- 6.2.4.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.2.4.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.2.5 Canada
- 6.2.5.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.2.5.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3 Europe
- 6.3.1 Market size, by country, 2017 - 2028 (USD Million)
- 6.3.2 Market size, by service type, 2017 - 2028 (USD Million)
- 6.3.3 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3.4 Germany
- 6.3.4.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.3.4.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3.5 UK
- 6.3.5.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.3.5.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3.6 France
- 6.3.6.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.3.6.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3.7 Italy
- 6.3.7.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.3.7.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.3.8 Spain
- 6.3.8.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.3.8.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.4 Asia Pacific
- 6.4.1 Market size, by country, 2017 - 2028 (USD Million)
- 6.4.2 Market size, by service type, 2017 - 2028 (USD Million)
- 6.4.3 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.4.4 Japan
- 6.4.4.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.4.4.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.4.5 China
- 6.4.5.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.4.5.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.4.6 India
- 6.4.6.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.4.6.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.4.7 Australia
- 6.4.7.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.4.7.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.5 Latin America
- 6.5.1 Market size, by country, 2017 - 2028 (USD Million)
- 6.5.2 Market size, by service type, 2017 - 2028 (USD Million)
- 6.5.3 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.5.4 Brazil
- 6.5.4.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.5.4.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.5.5 Mexico
- 6.5.5.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.5.5.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.6 Middle East & Africa
- 6.6.1 Market size, by country, 2017 - 2028 (USD Million)
- 6.6.2 Market size, by service type, 2017 - 2028 (USD Million)
- 6.6.3 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.6.4 South Africa
- 6.6.4.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.6.4.2 Market size, by end-use, 2017 - 2028 (USD Million)
- 6.6.5 Saudi Arabia
- 6.6.5.1 Market size, by service type, 2017 - 2028 (USD Million)
- 6.6.5.2 Market size, by end-use, 2017 - 2028 (USD Million)
Chapter 7 Company Profiles
- 7.1 Competitive dashboard, 2021
- 7.2 Charles River Laboratories International, Inc
- 7.2.1 Business overview
- 7.2.2 Financial data
- 7.2.3 Product landscape
- 7.2.4 Strategic outlook
- 7.2.5 SWOT analysis
- 7.3 Alturas Analytics, Inc.
- 7.3.1 Business overview
- 7.3.2 Financial data
- 7.3.3 Product landscape
- 7.3.4 Strategic outlook
- 7.3.5 SWOT analysis
- 7.4 BGI Group
- 7.4.1 Business overview
- 7.4.2 Financial data
- 7.4.3 Product landscape
- 7.4.4 Strategic outlook
- 7.4.5 SWOT analysis
- 7.5 Creative Proteomics
- 7.5.1 Business overview
- 7.5.2 Financial data
- 7.5.3 Product landscape
- 7.5.4 Strategic outlook
- 7.5.5 SWOT analysis
- 7.6 Eurofins Scientific
- 7.6.1 Business overview
- 7.6.2 Financial data
- 7.6.3 Product landscape
- 7.6.4 Strategic outlook
- 7.6.5 SWOT analysis
- 7.7 Evotec SE
- 7.7.1 Business overview
- 7.7.2 Financial data
- 7.7.3 Product landscape
- 7.7.4 Strategic outlook
- 7.7.5 SWOT analysis
- 7.8 Inotiv, Inc. (formerly Bioanalytical Systems, Inc.)
- 7.8.1 Business overview
- 7.8.2 Financial data
- 7.8.3 Product landscape
- 7.8.4 Strategic outlook
- 7.8.5 SWOT analysis
- 7.9 Labcorp Drug Development
- 7.9.1 Business overview
- 7.9.2 Financial data
- 7.9.3 Product landscape
- 7.9.4 Strategic outlook
- 7.9.5 SWOT analysis
- 7.10 MtoZ-Biolabs Inc.
- 7.10.1 Business overview
- 7.10.2 Financial data
- 7.10.3 Product landscape
- 7.10.4 Strategic outlook
- 7.10.5 SWOT analysis
- 7.11 PPD Inc. (part of Thermo Fisher Scientific, Inc.)
- 7.11.1 Business overview
- 7.11.2 Financial data
- 7.11.3 Product landscape
- 7.11.4 Strategic outlook
- 7.11.5 SWOT analysis
- 7.12 WuXi AppTec
- 7.12.1 Business overview
- 7.12.2 Financial data
- 7.12.3 Product landscape
- 7.12.4 Strategic outlook
- 7.12.5 SWOT analysis
- 7.13 MS Bioworks
- 7.13.1 Business overview
- 7.13.2 Financial data
- 7.13.3 Product landscape
- 7.13.4 Strategic outlook
- 7.13.5 SWOT analysis
- 7.14 Novatia LLC
- 7.14.1 Business overview
- 7.14.2 Financial data
- 7.14.3 Product landscape
- 7.14.4 Strategic outlook
- 7.14.5 SWOT analysis
- 7.15 Alphalyse
- 7.15.1 Business overview
- 7.15.2 Financial data
- 7.15.3 Product landscape
- 7.15.4 Strategic outlook
- 7.15.5 SWOT analysis
- 7.16 Metabolon, Inc.
- 7.16.1 Business overview
- 7.16.2 Financial data
- 7.16.3 Product landscape
- 7.16.4 Strategic outlook
- 7.16.5 SWOT analysis
- 7.17 biocrates life sciences ag
- 7.17.1 Business overview
- 7.17.2 Financial data
- 7.17.3 Product landscape
- 7.17.4 Strategic outlook
- 7.17.5 SWOT analysis
- 7.18 Biognosys
- 7.18.1 Business overview
- 7.18.2 Financial data
- 7.18.3 Product landscape
- 7.18.4 Strategic outlook
- 7.18.5 SWOT analysis
- 7.19 Proteome Sciences
- 7.19.1 Business overview
- 7.19.2 Financial data
- 7.19.3 Product landscape
- 7.19.4 Strategic outlook
- 7.19.5 SWOT analysis
- 7.20 Rapid Novor, Inc
- 7.20.1 Business overview
- 7.20.2 Financial data
- 7.20.3 Product landscape
- 7.20.4 Strategic outlook
- 7.20.5 SWOT analysis
- 7.21 iBET
- 7.21.1 Business overview
- 7.21.2 Financial data
- 7.21.3 Product landscape
- 7.21.4 Strategic outlook
- 7.21.5 SWOT analysis
- 7.22 BioCAT GmbH
- 7.22.1 Business overview
- 7.22.2 Financial data
- 7.22.3 Product landscape
- 7.22.4 Strategic outlook
- 7.22.5 SWOT analysis
- 7.23 Olink Proteomics AB
- 7.23.1 Business overview
- 7.23.2 Financial data
- 7.23.3 Product landscape
- 7.23.4 Strategic outlook
- 7.23.5 SWOT analysis
- 7.24 AxisPharm LLC
- 7.24.1 Business overview
- 7.24.2 Financial data
- 7.24.3 Product landscape
- 7.24.4 Strategic outlook
- 7.24.5 SWOT analysis
- 7.25 Somalogic Inc
- 7.25.1 Business overview
- 7.25.2 Financial data
- 7.25.3 Product landscape
- 7.25.4 Strategic outlook
- 7.25.5 SWOT analysis
- 7.26 Seer Inc
- 7.26.1 Business overview
- 7.26.2 Financial data
- 7.26.3 Product landscape
- 7.26.4 Strategic outlook
- 7.26.5 SWOT analysis